A new proof-of-concept in bacterial reduction : antimicrobial action of violet-blue light (405 nm) in ex vivo stored plasma
- Submitting institution
-
University of Strathclyde
- Unit of assessment
- 12 - Engineering
- Output identifier
- 111818937
- Type
- D - Journal article
- DOI
-
10.1155/2016/2920514
- Title of journal
- Journal of Blood Transfusion
- Article number
- 2920514
- First page
- -
- Volume
- 2016
- Issue
- -
- ISSN
- 2090-9187
- Open access status
- Compliant
- Month of publication
- September
- Year of publication
- 2016
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- 5 - Biological Sciences
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
4
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Led to a joint patent application (WO2017062260A2) between the University of Strathclyde and the US Food and Drug Administration (FDA), and an invitation from Dr Chintamani Atreya (Associate Director for Research, FDA Office of Blood Research and Review) to present at the 2018 international FDA Workshop on Pathogen Reduction Technologies for Blood Safety (doi: 10.1111/trf.15344; page 2, Line 9, https://www.fda.gov/media/123888/download). It led to EPSRC-IAA funding (EP/R51178X/1, £9,992), an EPSRC-funded studentship (2018-22), and an EPSRC National Productivity Investment Fund Innovation Placement (EP/S515620/1). The FDA entered into a cooperative research agreement with a US company to develop the technology (April 2019, confidential).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -